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Abstract The extent of drug binding to plasma proteins,
determined by measuring the free active fraction, has a
significant effect on the pharmacokinetics and pharmacody-
namics of a drug. It is therefore highly important to estimate
drug-binding ability to these macromolecules in the early
stages of drug discovery and in clinical practice. Traditionally,
equilibrium dialysis is used, and is presented as the reference
method, but it suffers from many drawbacks. In an attempt to
circumvent these, a vast array of different methods has been
developed. This review focuses on the most important
approaches used to characterize drug–protein binding. A
description of the principle of each method with its inherent
strengths and weaknesses is outlined. The binding affinity
ranges, information accessibility, material consumption, and
throughput are compared for each method. Finally, a
discussion is included to help users choose the most suitable
approach from among the wealth of methods presented.
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ACE Affinity capillary electrophoresis (mobility shift
assay)
AGP α1-Acid glycoprotein
BGE Background electrolyte
BSA Bovine serum albumin
CD Circular dichroism
CE Capillary electrophoresis
CE/FA Capillary electrophoresis/frontal analysis
CZE Capillary zone electrophoresis
D Drug
DP Drug–protein complex
DSC Differential scanning calorimetry
ED Equilibrium dialysis
FA Frontal analysis
FACCE Continuous capillary electrophoresis frontal
analysis
HD Hummel–Dreyer method
HDL High-density lipoproteins
HPAC High-performance affinity chromatography
HSA Human serum albumin
IR Infrared
ISRP Internal-surface reversed phase
ITC Isothermal titration calorimetry
Ka Association constant
Kd Dissociation constant
koff Dissociation rate constant
kon Association rate constant
LC Liquid chromatography
LDL Low-density lipoproteins
LIF Laser-induced fluorescence
m Total number of different classes of binding sites
MS Mass spectrometry
n Number of binding sites with the same affinity
per protein molecule
NMR Nuclear magnetic resonance
NSB Nonspecific binding
ORD Optical rotatory dispersion
P Protein
PAMPA Parallel artificial membrane assay
r Number of total drugs bound per protein
SEC Size-exclusion chromatography
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UF Ultrafiltration
VACE Vacancy affinity capillary electrophoresis
VP Vacancy peak method
ZE Zonal elution
ΔCp Heat capacity change
ΔG Gibbs free energy
ΔH Enthalpy of the binding reaction
ΔS Entropy change
μ Electrophoretic mobility
Introduction
After being distributed in circulating blood, drugs bind to
plasma proteins in varying degrees. In general, such binding is
reversible, and an equilibrium exists between bound and free
molecular species. It is commonly stated that unless there is a
specific transport system, only the free drugmolecules are able
to cross membrane barriers and be distributed to tissues to
undergo metabolism and glomerular filtration. Only the free
drug fraction is able to exert pharmacological and/or toxico-
logical effects [1–3] (Fig. 1). Thus, drug–plasma-protein
binding is critically involved in drug pharmacokinetics (i.e.,
absorption, distribution, metabolism, and elimination) and
pharmacodynamics (pharmacological effects). Plasma-protein
binding has, hence, been considered, along with solubility,
lipophilicity, ionization, and metabolic properties, as a key
piece of the data characterizing any compound, and must be
evaluated in the early stages of drug discovery [4]. Although
there may be many components in plasma that are capable of
binding drugs, two major proteins, human serum albumin
(HSA) and α1-acid glycoprotein (AGP), are present in
relatively high quantities and able to bind a broad variety
of drugs with sufficient affinity to have a significant effect on
drug disposition and action [5]. Globulins and lipoproteins
may also play a role to a lesser degree [6]. Many methods
have been proposed to assess protein-binding abilities based
on diverse analytical tools that can be divided into separative
and non-separative approaches. This review deals with the
main methods developed to characterize drug–plasma protein
interactions. The strengths and weaknesses of each method
and a comparison of these different assays in terms of
binding affinity ranges, information accessibility, material
consumption, and throughput are treated. Finally, a discussion
is included to help users to choose the most suitable approach
for their interacting system.
Drug–protein binding: theoretical description
The binding of a drug to a protein can be viewed as a
reversible and rapid equilibrium process governed by the law
of mass action. Irreversible binding of some drugs to plasma
proteins has nevertheless also been demonstrated [7, 8].
In the simplest case, assuming there is only one
reversible-binding site on the protein for a drug molecule,
binding between the drug and the protein can be described
by the following equilibrium [9]:
D½  þ P½   kof f!
kon
DP½  ð1Þ
where [D], [P], and [DP] are the free drug, free protein, and
drug–protein complex concentrations, respectively, and kon and
koff are the association and dissociation rate constants. At
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equilibrium, the rate of association is equal to the rate of
dissociation. Thus the association constant (Ka) can be defined
as follows:
Ka ¼ konkoff ¼
DP½ 
D½   P½  ð2Þ
The dissociation constant, Kd, which is the reciprocal of
Ka is also often reported. It represents the concentration of
free drug that occupies half of the overall acceptor sites at
equilibrium [8].
Another important property to introduce is the number of
total drugs bound per protein or the fraction of total binding
sites occupied. This is represented by the letter r (Eq. 3):
r ¼ DP½ 
P½  þ DP½  ¼
n  Ka  D½ 
1þ Ka  D½  ð3Þ
where n is the maximum number of binding sites on the pro-
tein. In Eq. 3, it is assumed that the n binding sites on the
protein have the same affinity constant for the drug but a pro-
tein can have several classes of n binding sites, each with its
own Ka value. Equation 3 can thus be rewritten as Eq. 4, where
m is the total number of different classes of binding sites:
r ¼
Xm
i¼1
ni  kai  D½ 
1þ Kai  D½  ð4Þ
Equation 4 assumes that the individual binding regions on
the protein have independent affinities for the solute. Such an
assumption is true when allosteric interactions are not present.
If this is not the case, thenmore complex reactionmodels have
to be used. Another assumption in these equations is that the
binding of the drug to each region on the protein can be
described by a single-step, reversible process [10].
The different approaches used to assess drug–protein
binding
The approaches used to investigate drug–protein interac-
tions are divided into separative and non-separative
methods (Fig. 2). The first group involves the separation
of the free ligand from the bound species and is used to
determine directly either the unbound drug or the bound
drug concentration [11]. The second group relies on
detection of a change in a physicochemical property of
either the ligand or the protein because of the binding [12].
Separative methods
Equilibrium dialysis and related techniques
Equilibrium dialysis (ED) and related techniques are based
on differences in molecular size and/or weight. In a
standard ED experiment, two compartments are separated
by a semipermeable membrane that acts as a molecular
sieve to allow only molecules smaller than a certain
molecular weight to permeate through it. It is thus (ideally)
perfectly permeable to the drug and impermeable to the
protein and the drug–protein complex. One compartment
contains the protein sample and the second, the tested drug.
After a defined incubation time, equilibrium is reached, and
the free drug fraction can be measured in the second
compartment.
ED has been the method most widely used to study
drug–protein interactions. Moreover, it is performed in
solution, and true equilibrium is maintained during the
whole experiment. Thus, ED is regarded as the reference
method. ED suffers, however, from many drawbacks.
Equilibration times are long (typically 12–48 h), and an
initial set of studies has to be performed to determine the
time necessary for the system to reach equilibrium [13].
Devices based on a 96-well format have been proposed to
enhance the throughput [14, 15] and are now commercially
available (Equilibrium Dialyzer-96 from Harvard Biosciences
(Holliston, MA, USA), Rapid Equilibrium Device from
Thermo Scientific/Pierce (Rockford, IL, USA), Micro Equi-
librium Dialysis Device from HTdialysis LLC (Gales Ferry,
CT, USA)). Another potential problem associated with ED is
the volume shift associated with the oncotic pressure that
takes place because of the semi-permeable membrane and the
presence of proteins [16]. This volume change can be as
large as +10 to +30% [17]. Nonspecific adsorption of drugs
or proteins on the cell walls and on the dialysis membrane
can also occur [18]. This “parasitic” binding can be higher
than 50% of the total concentration [8]. Moreover, the
Donnan effect may arise for charged proteins and distort the
interaction measurements [19]. Finally, poor aqueous solu-
bility of the compounds may also be problematic and limit
the use of ED.
Ultrafiltration (UF) has been proposed as a rapid
alternative to ED. This method is very similar except that
the analysis speed is increased by application of pressure to
force the solution through the membrane. Nevertheless,
issues also encountered in ED, such as the potential
nonspecific binding of the compounds to the filter
membrane, the Donnan effect, and protein leakage may
arise [6]. Although some authors [18, 20] considered the
application of a pressure during the separation process to be
detrimental for the stability of the binding equilibrium,
other work showed that UF is indeed performed under
equilibrium conditions [21]. Because kits are commercially
available even in a 96-well format (Millipore, Bedford,
MA, USA; Harvard Bioscience, Holliston, MA, USA) and
because this technique is simple to perform, it is still often
used at the drug discovery stage to rank compounds on the
basis of plasma protein binding, and for drug therapeutic
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monitoring, and pharmacokinetic and pharmacodynamic
studies in clinical laboratories.
In ultracentrifugation (UC), another related technique, a
solution of drug and protein mixed together is placed in a
centrifugal field. Centrifugation is continued until all the
protein and the drug–protein complex sediment to the bottom
of the tube. Because the sedimentation coefficient of the drug
is generally very small compared with that of the protein, the
free drug remains in the supernatant where it can be
quantified. UC has the advantage of eliminating problems
associated with membrane effects (e.g., the Donnan effect and
membrane adsorption). However, the equipment used for UC
is expensive in contrast with that used for ED and UF.
Moreover, comparative studies with different types of drug
revealed that quantitative discrepancies occurred between
results obtained by ED and UC because of estimation of the
free drug concentration, which can be affected by physical
phenomena such as sedimentation, back diffusion and
viscosity [8, 22]. For example, the error due to sedimentation
of the drug can be as large as 10% for drugs of 300 Da and up
to 40% for high-mass drugs (e.g., suramin, 1297 Da) [23].
These issues, combined with its low throughput (even for
modern apparatus), have rendered this approach unattractive.
Parallel artificial membrane assay
The parallel artificial membrane permeability assay (PAMPA)
was originally developed to enable prediction of drug passive
permeability through biological membranes. The assay is
based on a 96-well filter plate coated with an artificial
membrane (made of phospholipids [24, 25] or solvent(s)
[26, 27]) used to separate two compartments, one containing
a buffer solution of the compounds to be tested (defined as
the donor compartment) and the other containing only fresh
buffer (defined as the acceptor compartment).
Làzaro et al. [28] used the PAMPA technique to measure
the kinetics of permeation of a compound through a
hexadecane or 1-octanol membrane in the presence and
absence of protein in the donor compartment. The free drug
concentration in the acceptor compartment is measured at
different times and the difference between the two experi-
ments is used to estimate the binding constant. The key
assumption in this approach is that only the free drug is able
to cross the membrane whereas both the protein and the
drug–protein complex are unable to do so. This assay has
been used to study the interaction between HSA and 11
drugs with different lipophilicity, and acidic and basic
character, and Kd values in the mmol L
−1 to μmol L−1 range.
Use of PAMPA in assessment of binding constants has
several advantages:
1. the absence of an equilibration time requirement and
the 96-well format render the assay faster than
traditional ED;
2. there is no volume change due to oncotic pressure
because the chemical membranes used are not water-
permeable; and
3. nonspecific adsorption is self-corrected.
However, the liquid membrane (hexadecane or 1-octanol)
must be chosen to allow the free drug to permeate through it
while the protein is retained in the donor compartment. The
membrane has to be chosen depending on the compound
studied, which can be problematic during batch analysis.
Finally, in comparison with ED, the analytical burden is more
or less identical as both methods use liquid chromatography–
mass spectrometry (LC–MS) or LC–MS–MS as readout.
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The use of PAMPA for drug–protein binding studies is able
to furnish the equilibrium binding constants. According to the
mathematical treatment of the data proposed, however, only a
1:1 model has been applied and no stoichiometric information
is available.
Liquid chromatographic techniques
Liquid chromatographic methods used to assess drug–protein
interactions can be divided into two main approaches depend-
ing on whether both interacting species are free in solution
(size-exclusion chromatography) or whether one component,
generally the protein, is immobilized on the chromatographic
support (affinity chromatography). Zonal elution (small-plug
injection) or frontal analysis (large-plug injection) can be
applied to both approaches. In zonal elution (ZE), the
retention time or the peak area is used to obtain the association
constants whereas frontal analysis (FA) quantification is based
on plateau height [29].
In size-exclusion chromatography (SEC), molecules in
solution are separated on the basis of their size or, more
precisely, on their hydrodynamic volume. Typically, a
mixture of drug and protein elutes through a column
packed with porous particles. The protein and drug–protein
complex molecules, which are too large to penetrate the
pores of the packing, elute first. Drug molecules, however,
which can penetrate or diffuse into the pores, elute later
[30]. Internal-surface reversed-phase (ISRP) supports,
based on the same principle of drug–protein separation,
have also been used to this end [31].
In SEC, proteins and ligands are both used free in
solution. As previously mentioned, different modes have
been reported, depending to the experimental setup. Drug
and protein can either be mixed and then injected in a large
plug into the column (FA) or small-plug injections (ZE) can
be applied to either the mixture of drug and protein (direct
separation method), to one of the interaction partners while
the other species is dissolved in the eluent (Hummel–
Dreyer, or HD, method), or to neat buffer while both
components are dissolved in the mobile phase (vacancy
peak, or VP, method) [29].
In drug–protein binding assays, SEC has attracted only
limited attention. Its drawbacks, for example low column
efficiency and poor protein recovery, have made this
approach rather inconvenient and rarely used nowadays
[18]. Furthermore, short column life-times have also been
criticized, even if modern columns are more robust.
High-performance affinity chromatography (HPAC) is
based on immobilization of a protein on a support and
injection of an interacting solute into the column. Drugs
with high affinity will interact with the immobilized
protein and will eluate later than drugs with no or less
affinity.
One of the main advantages that made this approach
valuable is its ability to use only small amounts of protein
for a large number of studies, because the same protein
preparation can be reused for multiple experiments. This
minimizes run-to-run variations. For example, columns
containing HSA immobilized on silica particles have been
used for 500–1000 injections [32]. Other interesting
features of HPAC include its ease of automation and ability
to study the behavior of both enantiomers of chiral drugs by
using a racemate once the enantiomeric resolution is
obtained on the column.
The main debated and critical aspect to take into
consideration when performing binding studies with HPAC
is the immobilization of the protein on the chromatographic
support. It is therefore important to consider the extent to
which this support will model the behavior of the same
protein in its soluble form. This is of crucial concern,
because the immobilization process can affect protein
activity by denaturation, improper orientation, or steric
hindrance at the binding sites to be studied. It can either
impede or artificially enhance the recognition process [33].
Moreover, the biochromatographic support detects any
ligand interactions with the stationary phase that can affect
the retention time. The matrix anchoring the protein has its
own potential retention capacity, which creates nonspecific
binding inducing lower precision for low-affinity com-
pounds [34, 35]. Very strong affinities may also be
challenging, because organic modifiers (up to 30–40%
[36, 37]) have to be used to elute compounds with very
strong affinity (>99% binding). These modifiers can alter
the conformation of the protein and the drug–protein
binding by disrupting non-polar interactions. This usually
reduces the measured binding of solutes to protein.
Albumin is the most studied plasma protein in HPAC.
Among the reported anchoring procedures, those employ-
ing the covalent binding of HSA to a silica diol or to a
silica epoxy matrix seemed to mimic well the process in
solution [38–40]. This lends support to the validity of using
immobilized HSA as a model for albumin in solution. In
contrast, in most studies there is only fair correlation
between results obtained by use of immobilized AGP and
those obtained in solution. Furthermore, the immobilization
procedure is more complex than for HSA [41, 42].
However, Xuan et al. [43] recently optimized the proce-
dure, and better results were obtained, which suggests it is
possible to use AGP columns to directly model the binding
of drugs to soluble AGP. Hage’s group [44] has also
recently immobilized high-density lipoproteins (HDL) on
silica columns with promising results.
As previously mentioned, HPAC can be performed in
two different setups (ZE and FA). ZE is most commonly
used to study drug interactions with serum proteins because
of its simplicity and, probably, because it is performed in
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the same mode as used for most analytical applications of
chromatography (i.e., a narrow plug of solute is injected
into a column while the solute’s elution time is monitored).
ZE is mainly used to provide information on the bound
fraction of a drug because the relative quantity of drug at
equilibrium bound to the immobilized protein vs. free in the
mobile phase is directly measured by the retention factor
(k 0 ¼ tr  tm=tm, where tr is the retention time of the drug
and tm is the retention time of an unretained solute) [29]. It
has been shown that a relative strong correlation exists
between the term k 0= k 0 þ 1ð Þ and the amount (%) of protein
binding observed in solution-phase studies. Therefore, a
quantitative reference curve linking k 0= k 0 þ 1ð Þ and the
protein binding percentage can be generated with a series
of well-known compounds. The binding of an unknown
compound can thus be determined using this reference curve.
ZE is a relatively rapid approach to access drug–protein
binding. It is an interesting method, yet some experimental
conditions (e.g., drug concentration, flow-rate, column length,
and back pressure) have to be optimized for each compound
before starting the binding study [32]. ZE can also be used to
study the kinetic rate of binding interactions [45, 46].
FA is based on the continuous infusion of ligand over a
protein target immobilized on the column while the amount
of eluted ligand is monitored. The saturation of the column
with the ligand results in a breakthrough curve in which the
mean position is related to the binding capacity of the
column as long as rapid association and dissociation
kinetics occur [47]. If experiments are repeated at different
drug concentrations, the association equilibrium constants
can be obtained, because the position of the breakthrough
curve is related to the concentration of applied solute, the
amount of protein in the column, and Ka [29]. Nevertheless,
this approach inconveniently requires a fairly large amount
of solute (∼50 mL of μmol L−1 drug solution) [48, 49].
Several papers [50–52] used MS as a detection method
to improve detection sensitivity, which, in turn, increased
the range of accessible affinity constants (Ka up to 10
12
mol−1L with MS vs. 108mol−1L with UV). As a result,
several screening applications demonstrated the capability
of HPAC–FA–MS to assess strong interactions between
biological systems, together with a relatively high through-
put [53]. The limiting factor with MS in affinity studies,
however, is the use of MS-friendly buffers capable of
retaining protein stability at the same time.
Capillary electrophoretic techniques
General advantages of capillary electrophoresis (CE)
include:
1. high efficiency and separation selectivity;
2. low sample and reagent consumption;
3. high speed of analysis;
4. ease of automation; and
5. ability to work under near-physiological conditions
(buffer pH and ionic strength).
Furthermore, in the particular field of drug–protein
binding studies, it provides the favorable possibility of
evaluating interactions in free solution [33, 54, 55].
However, CE also has drawbacks, for example the risk of
protein adsorption on the capillary walls and the low
detection limits of commonly used UV detectors. In order
to enhance sensitivity, a laser-induced fluorescence (LIF)
detection system has been used in the early stages of drug
discovery, as exemplified by the CE-based platform
developed at Cetek (Marlborough, MA, USA) to screen
crude natural extract libraries [56, 57]. Unfortunately,
because only few molecules possess native fluorescence,
labeling is often required. This can interfere with the
binding interactions, as illustrated in a recent study by
Pedersen et al. [58]. Another valuable alternative to
enlarge the range of binding constants assessable by CE
is an MS detection system. One issue of MS is the use of
MS-compatible buffers that will not alter the binding
process, just as in HPAC. MS hyphenation to CE in the
drug–protein binding field is not well developed [59–61],
and progress is needed to make this technique more
reliable, even though some groups have published prom-
ising results.
As for LC, both ZE (small-plug injection) and FA (large-
plug injection) can be applied in CE. In FA, both species
are mixed prior to injection. When large plugs are injected,
the resulting electropherograms consist of plateaus instead
of thin peaks, and quantification is made by measuring the
height of the resulting plateau. In ZE, a mixture of both
interacting species can be injected into the capillary
containing neat buffer. Another possibility is the injection
of only one of the binding partners while the other is
dissolved in the electrophoresis buffer. It is also possible to
inject neat buffer (without any drug and protein) into a
capillary filled with both interacting species. Ka can be
obtained either by quantification of peak areas or by
migration shift. All the different CE approaches with their
advantages and drawbacks are summarized in Table 1.
Because they have been extensively reviewed [33, 54, 62–
68], only capillary electrophoresis/frontal analysis (CE/FA)
and affinity capillary electrophoresis (ACE) will be dis-
cussed below. These approaches are the most widely used,
because of their simplicity and reliability.
In CE/FA, the interacting species are first mixed in the
sample vial. Upon attainment of the binding equilibrium, a
volume of sample sufficiently large to maintain equilibrium
during the electrophoretic run, generally 10–20% of the
effective capillary length, is introduced into the capillary [69,
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70]. The introduction of large volumes gives rise to the
appearance of plateaus. If the electrophoretic mobility of the
protein equals that of the drug–protein complex (μP=μDP),
the height of the free drug plateau is proportional to the free
drug concentration in the original sample [71]. By repeating
the analysis at different drug/protein ratios, both Ka and the
stoichiometry of the reaction can be assessed via non-linear
regression.
CE/FA remains popular for several reasons:
1. its ability to deal with multiple equilibria and to
characterize the reaction stoichiometry;
2. its robustness, because of to the plateaus formed;
3. its low material consumption (nL); and
4. the possibility offered to work with systems with fast
and slow kinetic reactions [72].
In ACE, the capillary is filled with buffer containing the
protein (P) in varying concentrations and a small amount of
drug (D) is injected into the capillary [66, 73]. Ka can be
calculated from the change in the electrophoretic mobility
of D upon complexation. Its migration time (tm) is confined
between two extreme values—the tm of D without any P in
the running buffer and the tm of D at high protein
concentration (saturation). If performed at different drug/
protein ratios, non-linear regression treatment of the data
provides Ka [33, 65, 73–76].
One protein sample can be used for screening many
different putative ligands in different buffers [65]. This makes
the approach valuable when material is scarce. Moreover,
protein preparations do not need to be highly purified, and
protein binding of racemic drugs may be performed by
injecting the racemic mixture directly. A precise value of the
drug concentration is not required. Notably, calculation of Ka
requires that the protein concentration at equilibrium be
approximated to the added P concentration in the capillary. If
this were held to be true, the protein concentration must be
larger than the drug concentration. It thus becomes difficult
to correctly assess the value of Ka for moderate-to-high-
affinity systems (Ka > 10
5mol−1L). Other disadvantages of
ACE are its inability to yield the reaction stoichiometry and
the difficulty of dealing with multiple equilibria. The
different Ka values can only be obtained when the change
in mobility with increasing complexation P! PD! PD2ð Þ is
proportional to the number of ligands. If this is not the case,
an appropriate model relating the mobility of all the
interacting species involved should be incorporated in the
data-processing procedure, which inevitably complicates
the interpretation of these data [64].
Table 1 Comparison of the different capillary electrophoretic approaches used to assess drug–protein binding
a As long as there is no complex dissociation during the analysis time, i.e. high affinity needed.
BGE, background electrolyte; D, drug; P, protein; [ ], concentration; K, equilibrium binding constant; n, number of binding sites with the same affinity per
protein molecule; μDP, complex mobility; μD, drug mobility; μP, protein mobility;↔, adequate K values; ↓, underestimated K values; ↑, overestimated K values;
CE/FA, capillary electrophoresis/frontal analysis; FACCE, continuous capillary electrophoresis frontal analysis; CZE, capillary zone electrophoresis; ACE,
affinity capillary electrophoresis (mobility shift assay); HD, Hummel–Dreyer method; VP, vacancy peak method; VACE, vacancy affinity capillary
electrophoresis.
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Non-separative methods
Spectroscopic techniques
Spectroscopic methods (UV–visible, fluorescence, infrared
(IR), nuclear magnetic resonance (NMR), optical rotatory
dispersion (ORD), and circular dichroism (CD)) are based
on the perturbation of the electronic and spectroscopic
energy levels of the ligand or the protein by the binding.
These methods can be performed in solution, which
enables true equilibrium measurements. Spectroscopic
methods have the great advantage of providing a better
understanding of the binding mechanism, in addition to
binding affinity constant measurement. They also facilitate
insight into three-dimensional protein structure, which in
turn enables elucidation of some complementary structural
and conformational variations of a protein molecule
resulting from ligand attachment [18]. Changes in the UV
or visible absorption spectrum of a drug may be interpreted
in terms of the polarity of a drug binding site. Fluorescence
spectroscopy helps in identification of the binding site of a
drug and can also be used to calculate the binding distance
between the fluorophore on the protein and the drug [77].
IR is an excellent tool to study secondary structure of the
protein. NMR spectroscopy indicates which groups or parts of
a protein molecule are involved in the binding process, and
CD yields information about the three-dimensional structure
of the drug-binding site [78–81]. A new trend in drug–protein
interaction research is the use of different spectroscopic
analyses combined with computational methods (molecular
docking) to obtain a clear picture of the mode of interaction
of the binding partners [77, 82].
Spectroscopic approaches are successful mainly for
high-affinity binding sites and are not very powerful for
studying multiple equilibria. This is because the analytical
response is not a direct measure of the extent of binding but
instead is rather proportional to it [13, 83]. Another critical
point is the lack of sensitivity of these methods, which
seriously limits their wider use. For example, in IR,
samples of mmol L−1 concentration have to be used. Such
concentrations may lead to solubility problems and
nonspecific aggregation [18, 84].
Calorimetric techniques
Two calorimetric approaches are used to study drug–protein
interactions: isothermal titration calorimetry (ITC) and
differential scanning calorimetry (DSC).
ITC is the calorimetric approach most used to investigate
biomolecular interactions. It measures one of the most
fundamental characteristics of molecular complex forma-
tion, i.e. heat uptake or release. Typically, an ITC
experiment consists of successive additions of a drug to a
solution of protein contained in a reaction cell. Each
addition of ligand to the protein sample leads to the
formation of a specific amount of ligand–protein complex,
according to the binding affinity which can be evaluated by
monitoring the heat release [85–89].
ITC experiments can be designed with molecules of
arbitrary size and “spectroscopically silent” compounds.
Moreover there is no need for derivatization or protein
immobilization on a support. However, very high and very
low-affinity processes cannot be studied by ITC, and
sometimes the large amount of material required for
accurate measurements makes ITC experiments impracti-
cable [86]. Its low throughput may also be an issue, because
the time required to run a full titration experiment is at least
2.5 h and usually even longer. In this setup, the thermal
equilibration of the measurement cell after ligand addition
can easily take an additional 30–60 min [90]. Finally, as for
all non-separation techniques, the samples have to be
highly purified.
DSC was primarily developed to characterize protein
stability and folding. The instrumentation used for DSC
experiments is very similar to that used for ITC. The setup
is nevertheless different, because the reaction cell contain-
ing a mixture of drug and protein is heated at a controlled
rate. When a small molecule binds preferentially to the
native form of a protein, the drug stabilizes the protein and
the transition midpoint of the protein–ligand complex (the
temperature at which 50% of the protein is in its native
conformation and the other 50% is denatured) thus occurs
at a higher temperature than the midpoint in the absence of
ligand. DSC is, therefore, an indirect method for measuring
binding constants, because Ka is estimated from measure-
ments of equilibrium between folded and unfolded protein
rather than bound and unbound forms [91].
The main interest in DSC is in its ability to estimate very
large binding constants (up to 1015mol−1L) [92] that cannot
be conveniently measured by other techniques. Its main
disadvantages are the very low throughput and the large
sample consumption.
The real strength of calorimetric methods is their ability
to provide a complete thermodynamic picture of the
binding reaction. They can therefore be depicted as
powerful tools with a high information content. The direct
thermodynamic observable is the heat associated with the
binding event, i.e. the enthalpy of the binding reaction
(ΔH). These methods can yield the equilibrium binding
constants, the entropy change (ΔS), the Gibbs free energy
(ΔG), and the stoichiometry of the association [93, 94].
Use of these thermodynamic data makes it possible to
deduce the interaction mechanism [95]. Moreover, because
the heat capacity change (ΔCp), obtained from experiments
performed at different temperatures reflects the burial of
polar and non-polar surfaces as a consequence of the
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binding reaction, calorimetric methods provide a link
between thermodynamic data and structural information
about macromolecules [86, 96].
Nowadays, ITC is regaining popularity in medicinal
chemistry laboratories, because knowledge of thermody-
namic data can aid rational drug design. A typical example
of a drug optimization strategy combining structural and
thermodynamic approaches is the development of high-
potency inhibitors of the HIV-1 protease [97]. In contrast,
only a few papers have studied the interaction between
small molecules and proteins by DSC [91, 92, 98, 99].
Questions may arise concerning the real strength of DSC
in this domain. A unique recent paper in the protein-
binding field [100] used DSC to show that plasma from
healthy individuals yields a reproducible signature ther-
mogram whereas DSC analysis of plasma from diseased
individuals reveals significant changes because of the
interaction of small molecules with plasma proteins. DSC
might thus provide a tool for disease screening and
monitoring.
Surface plasmon resonance-based assays
Surface plasmon resonance (SPR)-based techniques involve
immobilizing one reactant (the protein) on a surface and
monitoring its interaction with a second component (the
drug) in solution that flows over the surface [101, 102].
Basically, an SPR detector monitors changes in the
refractive index that occur as molecular complexes form
or break during the binding reaction at the sensor surface
anchoring one of the interaction partners [103]. This
response, also proportional to the mass of bound material,
is recorded in a sensorgram. Mathematical treatment of the
signal obtained gives the binding data.
Qualitatively, visual inspection of the response curves
indicates if complex formation takes place (increase of
response), reaches equilibrium and/or saturation (plateau),
and is reversible (decrease of response). It can also give
kinetic stability information about the complex formed.
Analysis of time and concentration-dependant response
curves can also provide quantitative information about the
stoichiometry of binding, equilibrium binding constants,
and kinetic rate constants [104].
Methods based on SPR are interesting for several reasons:
1. the lack of labeling requirement;
2. their ability to characterize binding reactions in real
time
3. the assessable quantitative information about the
binding events (affinity and kinetic rate constants); and
Table 2 Main features, advantages and disadvantages of the different methods used to assess drug–protein binding
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4. the small amount of material used (for typical analyses
a few micrograms of a protein are required to make a
single surface in typical analyses).
Furthermore, a wide range of affinity constants (Kd≈
mmol L−1–pmol L−1) and kinetic rate constants (kon from
103 to 108mol−1L s−1, koff from 10
−6 to 1 s−1) can be
assessed [105]. However, as for HPAC, an often criticized
aspect is the immobilization of the protein on the sensor
surface [104, 106–109]. SPR has been used successfully to
rank drug molecules into weak, medium, and strong binders
to HSA and AGP but encountered limitations in Ka
determination for some compounds, because of complex
data and behavior [110, 42]. It is worth remembering that the
refractive index change per molecule is related linearly to the
molecular weight of the compound that binds the immobilized
protein. Therefore, when working with small-molecular-
weight drugs that bind to high molecular weight proteins, it
might be difficult to obtain reliable data without specific
equipment. Finally, SPR-based technology has a moderate
throughput rate and is currently not suited to the study of a
large number of compounds. The commercialization of higher-
throughput devices such as the Biacore A100 with its parallel
flow cells on a single chip may open new application fields in
the drug-discovery process. Nevertheless, the equipment and
maintenance costs of this technique might be discouraging.
Method selection
There are probably no general rules or flowcharts for
selecting the best experimental method to study drug–
protein binding, yet it may be helpful to present some of the
pertinent factors to take into account when choosing a
method to study an interaction system. Many of these
considerations are deduced from comparison of the advan-
tages and limitations of each technique summarized in
Table 2. Additionally, because of the complementary nature
of the techniques, often only a combination of different
approaches enables the scientist to catch a glimpse of the
complex world of protein-binding studies.
The first considerations are the type of information
required and the number of compounds to test. In early drug
discovery, rather simple information is needed. The binding
percentage may be sufficient so long as the throughput is high
enough. At that stage, PAMPA and HPAC could be good
approaches, because of the 96-well technology and the
information about the amount of binding (%) available from
a single injection, respectively. In HPAC and in CE, the
binding affinity constants can be obtained relatively rapidly.
Moreover, CE experiments can be performed in parallel
because of the multiplexed CE instruments available (e.g., the
96-capillary format instrument from CombiSep (Ames, IA,
USA)). Recently, microchip CE has also been used to
characterize interactions, in order to reduce reagent consump-
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Fig. 3 Range of binding constants (log Ka) assessable by the different
methods used to study drug–protein interactions. ED, equilibrium
dialysis; UF, ultrafiltration; PAMPA, parallel artificial membrane
permeability assay; HPAC/ZE, high-performance affinity chromatogra-
phy/zonal elution approach; HPAC/FA, high-performance affinity chro-
matography/frontal analysis approach; ACE, affinity capillary
electrophoresis (mobility shift assay); CE/FA, capillary electrophoresis/
frontal analysis; Spectro., spectroscopic assays; ITC, isothermal titration
calorimetry; comp., competition studies; titration, titration studies; DSC,
differential scanning calorimetry; SPR, surface plasmon resonance-based
assays
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tion and analysis time [111–113]. HPAC, however, requires
the immobilization of one of the interacting partners on the
chromatographic support, which can require significant time
to optimize the anchoring procedure. Moreover, preliminary
studies have to be performed to check the extent to which
the support models the protein behavior in solution. For
some proteins, the problem of protein immobilization can
also lead to the complete loss of its binding properties. The
same is true for SPR techniques. In contrast, when rapid and
simple method development is a priority, CE is a really good
choice [114].
In advanced drug discovery or development stages,
spectroscopic and/or calorimetric approaches are the methods
of choice to obtain a complete view of the binding
mechanisms, as illustrated elsewhere [115, 116]. Kinetics
information, obtained mainly by SPR, might be of great
importance in the understanding of some biological phe-
nomena. In the particular case of drug–protein binding, it is
still a matter of debate whether or not the kinetics should be
considered when modeling a drug pharmacokinetic profile.
In most cases, however, it seems not to be necessary because
the time scale of protein-binding equilibration is much
shorter than that of other pharmacokinetic processes, for
example drug distribution and elimination. Thus, the
assumption of an instantaneous binding equilibrium is valid
in most practical situations [117]. The stoichiometry of the
system should also be taken into consideration, because
some methods (spectroscopic approaches, SPR) are quite
successful when applied to binding systems of simple 1:1
stoichiometry but are relatively ineffective or imply compli-
cated data analysis for systems having multiple equilibria
[13].
Another important consideration is the range of Ka
values assessable with each method (Fig. 3). Spectroscopic
approaches are better suited to high-affinity systems whereas
PAMPA, ED, CE, and HPAC are adequate for measurement
of weak to moderate affinity. More specific interactions, i.e.
higher affinities, can easily be characterized by ITC whereas
very-high-affinity systems require DSC. Most studies
dealing with calorimetry are indeed found in the drug
design field, i.e. interaction with a defined target (strong
interaction), and only few have reported interactions of small-
molecular-weight drugs with plasma proteins (polyphenol–
BSA [118], Ni2+–HSA [119], penicillins–HSA [94],
surfactants–HSA [120]).
The physicochemical properties of the studied com-
pounds and the amount of material available may also
condition the choice of the method. If solubility is low,
spectroscopic and calorimetric approaches may fail whereas
PAMPA, HPAC, or SPR may be adequate, because of their
greater sensitivity. A limitation of PAMPA could, never-
theless, be the analysis of very lipophilic drugs that might
stay trapped in the membrane. When material is scarce, CE
should be considered as it consumes only minute amounts
of sample, in contrast with spectroscopic and calorimetric
approaches.
The classical methods (ED, UF, and UC) are not suited
to study interactions between compounds of approximately
the same size, because they are based on differences in
molecular size. Typically, protein–protein interactions can-
not be analyzed by such systems. SPR that senses changes
proportional to the mass of bound material on the sensor
chip may be a fine alternative.
Samples of low purity require separation techniques,
such as HPAC or CE, unless a purification step is
performed beforehand. Finally, the instruments available
in the operator’s laboratory, his/her own experience with a
type of method, and the costs involved may also be
considered.
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